HYBRIGENICS: Hybrigenics unveils the objectives of its strategic plan: EUR 60 million in sales targeted by 2025 – 05/12/2022 at 08:00


Ambition: accelerate synergies between subsidiaries to become a key player in the field of drug development

Illkirch, December 5, 2022



Hybrigenics SA (Euronext Paris – FR0004153930 – ALHYG)

presented its strategic plan to guide Hybrigenics’ strategy in the value chain of therapeutic treatments serving players in the pharmaceutical and biotechnology industry.

This strategic plan was structured in three phases, launched in parallel:

  • The sentence ”

    Renaissance

    “, which started at the end of 2021 and will run until 2023, will focus on asserting a new identity to clearly identify the Hybrigenics Group as a player in the pharmaceutical and biotechnology industry, and on restoring growth and generating cash.

  • The sentence ”

    Transformation

    “, which will continue until 2025, will evolve Hybrigenics’ business model towards the synergistic integration of technologies, making the Group a forerunner in the value chain for the development of therapeutic treatments.

  • The sentence ”

    Expansion”

    which will begin in 2024, will see the Group’s international deployment accelerate, helping to increase turnover.

At the end of the plan, the Hybrigenics Group aims to achieve a total turnover with all of its subsidiaries (Stemcis, Inoviem Scientific, Bcell Design, Pims Technology) of

€60m by 2025

compared to total expected revenue of around €2 million in 2022.

The presentation of Hybrigenics’ strategic plan is available on the company’s website ( www.hybrigenics.com ), Documents section.


About Hybrigenics


Hybrigenics is a listed biopharmaceutical company (ALHYG) in Paris on the Euronext Growth market of Euronext, eligible for the PEA-PME.

Hybrigenics and its subsidiaries make up the DMS Biotech division, which supports the development strategy of DMS Group (Euronext Paris – FR0012202497 – DGM) in the field of biotechnology. It specializes in the development of biotherapy solutions in different therapeutic areas.

More information at www.hybrigenics.com.


Hybrigenics

is listed on the Euronext Growth market of Euronext Paris

ISIN: FR0004153930 – Memo: ALHYG – PEA-PME eligible

Hybrigenics


Leone ATAYI

Executive Director

[email protected]

09 71 04 32 63


This post has the “? Actusnews SECURITY MASTER” service.


– SECURITY MASTER Key:

yWhrk8qZaGqWy2pyaJ1umWNqbWtmlmScZ5Sel2mbk5/GaG9mxZxmbprGZnBomW1p

– To check this key:

https://www.security-master-key.com.



Regulated information:


Inside information:

– Other press releases


Full and original press release in PDF format:

https://www.actusnews.com/news/77483-hybrigenics_cp_objectives-plan-strategique_05122022.pdf

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com



Source link -86